Major shareholder announcement / Porter Orlin LLC
06-10-11 kl. 6/10 2011 12:33 | NeuroSearch 3,50 (-0,28%)
Se flere nyheder om NeuroSearch
06.10.2011
NeuroSeach A/S (NEUR) has received information from Porter Orlin LLC, New York,
that the company has increased its voting rights in NeuroSearch A/S attached to
shares owned by other companies.
Hereafter, Porter Orlin LLC administers a total of 1,306,667 shares of DKK 20
nominal value corresponding to a total ownership and voting rights of 5.32%.
Patrik Dahlen
CEO
Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil®, a unique drug in Phase III for the
treatment of the motor symptoms of Huntington's disease. 
Fonds.23-11 - Major shareholder - Porter Orlin LLC - UK.pdf
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 3,50 |
|---|---|
| ÆNDRING | -0,01 (-0,28%) |
| ÅBEN | 3,57 |
| SIDSTE LUK | 3,51 |
| DEBAT | - |
 |
